Attached files
| file | filename |
|---|---|
| 10-K - 10-K 12.31.16 - CALADRIUS BIOSCIENCES, INC. | clbs-10kx20161231.htm |
| EX-32 - EXHIBIT 32 - CALADRIUS BIOSCIENCES, INC. | clbs-ex32_20161231.htm |
| EX-31.2 - EXHIBIT 31.2 - CALADRIUS BIOSCIENCES, INC. | clbs-ex312_20161231xq4.htm |
| EX-31.1 - EXHIBIT 31.1 - CALADRIUS BIOSCIENCES, INC. | clbs-ex311_20161231xq4.htm |
| EX-23.1 - EXHIBIT 23.1 GT - CALADRIUS BIOSCIENCES, INC. | exh2312016.htm |
| EX-10.8 - EXHIBIT 10.8 DIRECTOR COMP POLICY - CALADRIUS BIOSCIENCES, INC. | exh1015directorcomppolicy.htm |
Exhibit 21.1
Subsidiaries of Caladrius Biosciences, Inc.
Entity | Percentage of Ownership | Location | ||
Caladrius Biosciences, Inc. | 100% | United States of America | ||
Stem Cell Technologies, Inc. | 100% | United States of America | ||
Amorcyte, LLC | 100% | United States of America | ||
PCT, LLC, a Caladrius Company | 80.1% | United States of America | ||
NeoStem Family Storage, LLC | 80.1% | United States of America | ||
Athelos Corporation (1) | 97% | United States of America | ||
PCT Allendale, LLC | 80.1% | United States of America | ||
NeoStem Oncology, LLC | 100% | United States of America | ||
(1) As of December 31, 2016, Becton Dickinson's ownership interest in Athelos Corporation was 1.6%.